Complications of BV-CHOP Therapy
The most common grade ≥3 complications of brentuximab vedotin combined with CHP (BV-CHOP) are neutropenia (35%), anemia (13%), diarrhea (6%), peripheral neuropathy (4%), and nausea (2%), with febrile neutropenia occurring in 14% of patients. 1
Hematologic Complications
Neutropenia is the most frequent severe complication:
- Grade ≥3 neutropenia occurs in 35% of patients 1
- Febrile neutropenia develops in 14% of patients 2
- Primary G-CSF prophylaxis was used in only 34% of patients in the pivotal trial, suggesting this complication is manageable with appropriate supportive care 2
Anemia affects 13% of patients at grade ≥3 severity 1, 2
Thrombocytopenia can occur but is less common than other cytopenias
Neurologic Complications
Peripheral neuropathy is a critical toxicity to monitor:
- Grade ≥3 peripheral neuropathy occurs in only 4% of patients with BV-CHP 1
- Overall peripheral neuropathy rates are similar between BV-CHP (52%) and standard CHOP (55%) 3
- Importantly, peripheral neuropathy associated with brentuximab vedotin continues to improve or resolve with long-term follow-up 1
- In the 5-year follow-up data, 72% of patients with peripheral neuropathy experienced resolution or improvement 4
This is a crucial distinction: by replacing vincristine with brentuximab vedotin, the regimen does not increase neuropathy risk compared to standard CHOP.
Gastrointestinal Complications
- Nausea: 22% any grade, 3% grade ≥3 2
- Diarrhea: 20% any grade, 6% grade ≥3 1, 2
- Vomiting: 16% any grade, 2% grade ≥3 2
- Mucositis: More common with BV-CHP than CHOP 2
Infectious Complications
- Pneumonia: 5% serious adverse reaction rate 2
- Sepsis: 3% serious adverse reaction rate 2
- Upper respiratory tract infections: 14% overall incidence 2
- Fatal adverse reactions from infection: 3% in the BV-CHP arm 2
Constitutional Symptoms
- Fatigue/asthenia: 35% any grade, 2% grade ≥3 2
- Pyrexia: 26% any grade, occurring ≥2% more frequently than with CHOP 2
Treatment Modifications Required
Dose delays occurred in 25% of patients receiving BV-CHP, most commonly due to:
- Neutropenia
- Peripheral neuropathy 2
Dose reductions were needed in 9% of patients, most often for peripheral neuropathy 2
Treatment discontinuation occurred in 7% of patients, primarily due to:
- Peripheral neuropathy
- Infection 2
Serious Adverse Reactions
Overall, 38% of BV-CHP patients experienced serious adverse reactions compared to 35% with CHOP 2. The most common serious adverse reactions were:
- Febrile neutropenia (14%)
- Pneumonia (5%)
- Pyrexia (4%)
- Sepsis (3%)
Critical Safety Considerations
Mortality: Fatal adverse reactions occurred in 3% of patients in the BV-CHP arm, most often from infection 2. This is comparable to the 4% rate in the CHOP arm.
Pulmonary toxicity: While not emphasized in the ECHELON-2 data, dyspnea occurs in 15% of patients (2% grade ≥3) 2
Hepatotoxicity: Reported as a serious adverse reaction in 2% of patients in other BV studies 2
Management Approach
- Implement G-CSF prophylaxis for patients at high risk of febrile neutropenia
- Monitor for peripheral neuropathy at each cycle; hold or reduce dose for grade 2-3 neuropathy per FDA labeling
- Aggressive supportive care for gastrointestinal symptoms
- Infection prophylaxis should be considered given the 14% febrile neutropenia rate
- Patient education about neuropathy symptoms and infection risk is essential
The safety profile of BV-CHP is manageable and does not significantly exceed that of standard CHOP, while providing superior efficacy outcomes with 5-year PFS of 51% versus 43% and OS of 70% versus 61% 4.